BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//The European School of Multimodality Imaging & Therapy (ESMIT) - ECPv6.15.11//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:The European School of Multimodality Imaging & Therapy (ESMIT)
X-ORIGINAL-URL:https://esmit.eanm.org
X-WR-CALDESC:Events for The European School of Multimodality Imaging & Therapy (ESMIT)
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Europe/Vienna
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20230326T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20231029T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20240331T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20241027T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20250330T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20251026T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20260329T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20261025T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20270328T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20271031T010000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=Europe/Vienna:20260410T133000
DTEND;TZID=Europe/Vienna:20260410T143000
DTSTAMP:20260419T052443
CREATED:20251004T070000Z
LAST-MODIFIED:20260410T073326Z
UID:2849-1775827800-1775831400@esmit.eanm.org
SUMMARY:Open your Heart on SPECT and PET Studies: Synergistic Information from the CT
DESCRIPTION:This webinar will cover synergetic information derived from the CT component in SPECT/CT and PET/CT examinations:  the first part we will focus on cardiac calcifications\, offering valuable insights into their detection and clinical relevance especially for myocardial perfusion scans. In the second half\, we will discuss incidental findings in the thorax\, helping clinicians recognize and interpret unexpected observations in SPECT/CT and PET/CT studies.  \n\n\n\n \n\n\n\n \n\n\n\n\n\n\n\nRegister nowEnrol in the live webinar now for free! Register now\n\n\n\n\n\n\n\n \n\n\n\n \n\n\n\nLearning Objectives\n\n\n\n \n\n\n\nThis webinar aims to equip attendees with practical knowledge that enhances diagnostic confidence\, facilitates interdisciplinary collaboration\, and improves patient outcomes in hybrid nuclear cardiology examination. Participants will gain a deeper understanding of: \n\n\n\n \n\n\n\n\nCardiac Calcifications with CT: Learn how to identify and assess cardiac calcifications using CT imaging\, recognize their clinical significance\, and understand their implications for cardiovascular disease risk stratification in PET/CT and SPECT/CT myocardial perfusion examinations\n\n\n\nIncidental Findings in the Thorax: Develop the ability to systematically evaluate incidental thoracic findings encountered in SPECT/CT and PET/CT studies\, differentiate between benign and pathological abnormalities\, and enhance decision-making for further clinical assessment.”info will come soon\n\n\n\n\n \n\n\n\n \n\n\n\nTarget Audience\n\n\n\n \n\n\n\n\nNuclear Medicine physicians\, Cardiologists with focus on cardiovascular imaging\, Radiologists\, Technologists\, Residents in Nuclear Medicine.\n\n\n\n\n \n\n\n\n \n\n\n\nFaculty\n\n\n\n \n\n\n\n\n\nManar BadarnahSpeaker \n\n\n\n\n\nChristoph RyffelSpeaker \n\n\n\n\n\nFederico CaobelliModerator \n\n\n\n\n\n\n\n\n\nEvent Overview
URL:https://esmit.eanm.org/event/open-your-heart-on-spect-and-pet-studies-synergistic-information-from-the-ct/
CATEGORIES:Live Webinars
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Vienna:20260327T133000
DTEND;TZID=Europe/Vienna:20260327T143000
DTSTAMP:20260419T052443
CREATED:20251004T070000Z
LAST-MODIFIED:20260320T084326Z
UID:2847-1774618200-1774621800@esmit.eanm.org
SUMMARY:FDG PET/CT in Inflammation and Infection: from Theory to Clinical Practice!
DESCRIPTION:Imaging of infection and inflammation has been part of nuclear medicine since the 1970s. Over the past two decades\, the growing role of FDG PET/CT in diagnosing and monitoring the treatment of a wide variety of infectious and inflammatory diseases has been recognised. As a result\, this technique has recently been adopted in several clinical guidelines. This webinar provides clinical case-based evidence to assist nuclear medicine physicians in recommending\, performing and interpreting FDG PET/CT examinations in patients with infectious and inflammatory disorders. \n\n\n\n \n\n\n\n\n\n\n\nRegister nowEnrol in the live webinar now for free! Register now\n\n\n\n\n\n\n\n \n\n\n\n \n\n\n\nLearning Objectives\n\n\n\n \n\n\n\n\nThe aim of this live webinar is to describe\, using illustrative clinical cases\, the role of FDG PET/CT in a variety of pathological conditions characterised by infection or inflammation\, with particular emphasis on strengths and limitations of FDG PET/CT.\n\n\n\n\n \n\n\n\n \n\n\n\nTarget Audience\n\n\n\n \n\n\n\n\nNuclear Medicine Physicians\, Residents\, Technologists\n\n\n\n\n \n\n\n\n \n\n\n\nFaculty\n\n\n\n \n\n\n\n\n\nAyah NawwarSpeaker \n\n\n\n\n\nDomenico AlbanoSpeaker \n\n\n\n\n\nSøren HessSpeaker \n\n\n\n\n\nLucia LeccisottiModerator \n\n\n\n\n\n\n\n\n\nEvent Overview
URL:https://esmit.eanm.org/event/fdg-pet-ct-in-inflammation-and-infection-from-theory-to-clinical-practice/
CATEGORIES:Live Webinars
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Vienna:20260313T133000
DTEND;TZID=Europe/Vienna:20260313T143000
DTSTAMP:20260419T052443
CREATED:20251004T070000Z
LAST-MODIFIED:20260302T091708Z
UID:2845-1773408600-1773412200@esmit.eanm.org
SUMMARY:Radiobiological Aspects of PRRT
DESCRIPTION:This webinar will examine the fundamental differences between targeted radionuclide therapy (TRT) and conventional external beam radiotherapy (EBRT)\, integrating physical\, dosimetric\, and radiobiological perspectives relevant to clinical practice. Drawing on the EANM–ESTRO joint session\, the first part will outline how TRT’s systemic administration\, patient-specific pharmacokinetics\, protracted low dose-rate delivery\, and highly heterogeneous intratumoral distribution distinguish it from the controlled\, high dose-rate\, fractionated paradigm of EBRT. Emphasis will be placed on implications for treatment planning\, activity prescription\, imaging-based dosimetry\, and the limitations of directly translating EBRT concepts such as uniform dose coverage and standard fractionation models to TRT. \n\n\n\nThe second part will focus on how absorbed dose\, dose rate\, and spatial heterogeneity influence biological effectiveness and clinical outcomes in TRT. Key topics include sublethal damage repair during continuous irradiation\, challenges in applying conventional radiobiological models\, the impact of microscopic dose non-uniformity (especially for β- versus α-emitting therapies)\, and the relationship between local tumor control and systemic effects\, including immune modulation. The session aims to equip nuclear medicine physicians and medical physicists with a conceptual framework to interpret dosimetry results\, personalize treatments\, and critically evaluate emerging combination strategies as TRT evolves toward a quantitatively driven radiotherapy modality. \n\n\n\n \n\n\n\n \n\n\n\n \n\n\n\n\n\n\n\nRegister nowEnrol in the live webinar now for free! Register now\n\n\n\n\n\n\n\n \n\n\n\n \n\n\n\nLearning Objectives\n\n\n\n \n\n\n\n\nDifferentiate the fundamental physical and clinical characteristics of TRT versus EBRT\, including source geometry\, temporal delivery\, dose-rate profiles\, and implications for treatment planning and prescription.\n\n\n\nExplain how pharmacokinetics and biodistribution govern absorbed dose in TRT\, and why activity administration alone is an insufficient surrogate for delivered dose and therapeutic effect.\n\n\n\nAssess the impact of dose rate and protracted irradiation on radiobiological response\, including sublethal damage repair\, limitations of conventional linear-quadratic modeling\, and consequences for tumor control and normal tissue toxicity.\n\n\n\nRecognize the clinical significance of spatial dose heterogeneity at organ\, tumor\, and cellular scales\, particularly differences between β-emitting and α-emitting radiopharmaceutical therapies.\n\n\n\nInterpret the relationship between dosimetry metrics and clinical outcomes\, including local control\, toxicity\, and potential systemic (immune-mediated) effects.\n\n\n\nApply these concepts to support patient-specific dosimetry\, treatment personalization\, and multidisciplinary decision-making in modern targeted radionuclide therapy practice.\n\n\n\n\n \n\n\n\n \n\n\n\nTarget Audience\n\n\n\n \n\n\n\n\nThis webinar is intended for nuclear medicine physicians and medical physicists involved in targeted radionuclide therapy\, including early-career professionals and practitioners seeking to deepen their understanding of the physical and radiobiological principles underpinning modern TRT practice.\n\n\n\n\n \n\n\n\n \n\n\n\nFaculty\n\n\n\n \n\n\n\n\n\nDavid Sánchez-ArtuñedoSpeaker \n\n\n\n\n\nZachary MorrisSpeaker \n\n\n\n\n\nSamantha TerryModerator \n\n\n\n\n\n\n\n\n\nEvent Overview
URL:https://esmit.eanm.org/event/radiobiological-aspects-of-prrt/
CATEGORIES:Live Webinars
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Vienna:20260220T133000
DTEND;TZID=Europe/Vienna:20260220T143000
DTSTAMP:20260419T052443
CREATED:20251004T070000Z
LAST-MODIFIED:20260217T091153Z
UID:2843-1771594200-1771597800@esmit.eanm.org
SUMMARY:Beyond Single Modality: The Future of Cancer Staging with Hybrid Scanners
DESCRIPTION:This webinar will be on the future of cancer staging with hybrid imaging technologies. Participants will gain an overview of advanced PET/CT\, SPECT/CT\, and PET/MRI systems\, learning how hybrid imaging enhances diagnostic accuracy and supports more precise clinical decisions.The session will explore the practical challenges technologists face when working with these cutting-edge systems\, including image acquisition\, processing\, and interpretation\, while highlighting the technical skills needed for effective operation.We’ll also discuss educational gaps and training opportunities for radiographers and technologists\, presenting strategies such as hands-on workshops\, e-learning\, and mentorship to support professional development.By the end of this webinar\, attendees will have a clear understanding of the evolving role of technologists in hybrid oncological imaging and be inspired to embrace innovation\, lifelong learning\, and interdisciplinary collaboration. \n\n\n\n \n\n\n\n \n\n\n\n \n\n\n\n\n\n\n\nRegister nowEnrol in the live webinar now for free! Register now\n\n\n\n\n\n\n\n \n\n\n\n \n\n\n\nLearning Objectives\n\n\n\n \n\n\n\n\nDescribe the most advanced hybrid imaging technologies used for oncological staging in nuclear medicine Understand the key features of PET/CT\, SPECT/CT\, and PET/MRI systems\n\n\n\nDistinguish the main advantages and limitations of hybrid modalities in clinical oncology\n\n\n\nUnderstand the added value of multimodality imaging compared with single-modality approaches Identify cases where hybrid imaging improves sensitivity\, specificity\, or diagnostic accuracy Recognize how functional-anatomical integration supports more precise clinical decisions\n\n\n\nAnalyze the main challenges faced by technologists in the acquisition\, processing\, and interpretation of hybrid imaging data Highlight practical issues (e.g.\, image registration\, calibration\, artifacts\, acquisition timing)Reflect on the technical skills required to operate hybrid systems effectively\n\n\n\nIdentify educational gaps and learning challenges encountered by radiographers/technologists when adopting new hybrid technologies Recognize organizational\, infrastructural\, and educational barriers (e.g.\, equipment availability\, supervision\, time constraints) Assess variations in training opportunities across European contexts\n\n\n\nPropose strategies and training programs for integrating hybrid skills into radiotherapy technician (RTM) programs\, fostering critical awareness of the evolving role of the technician in the context of hybrid oncology imaging.Suggest training models (advanced courses\, internships at centers of excellence\, e-learning\, hands-on workshops)Outline a roadmap for continuous development (on-the-job training\, certifications\, mentorships)\n\n\n\nPromote a proactive mindset toward technological innovation and self-development\n\n\n\n\n \n\n\n\n \n\n\n\nTarget Audience\n\n\n\n \n\n\n\n\nNuclear medicine Technologists\n\n\n\n\n \n\n\n\n \n\n\n\nFaculty\n\n\n\n \n\n\n\n\n\nOliver RamsaySpeaker \n\n\n\n\n\nNia HopsonSpeaker \n\n\n\n\n\nPaolo TurcoModerator \n\n\n\n\n\n\n\n\n\nEvent Overview
URL:https://esmit.eanm.org/event/beyond-single-modality-the-future-of-cancer-staging-with-hybrid-scanners/
CATEGORIES:Live Webinars
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Vienna:20260206T133000
DTEND;TZID=Europe/Vienna:20260206T143000
DTSTAMP:20260419T052443
CREATED:20251004T070000Z
LAST-MODIFIED:20260126T130413Z
UID:2840-1770384600-1770388200@esmit.eanm.org
SUMMARY:Innovations in Theranostics for Neuroblastoma
DESCRIPTION:This course provides a comprehensive update on instrumental and radiopharmaceutical innovations in the diagnosis and treatment of neuroblastoma. Participants will explore current and emerging imaging modalities\, with a comparative analysis of MIBG\, MFBF\, FDOPA\, and Gallium-based tracers\, highlighting their evolving roles in staging\, risk stratification\, and response assessment. \n\n\n\nThe course will address recent changes in clinical practice and the challenges these advancements pose for pediatric oncologists and nuclear medicine physicians\, emphasizing multidisciplinary decision-making. \n\n\n\nIn addition\, the program will review novel therapeutic strategies for refractory and relapsed neuroblastoma\, with a focus on radioligand therapy and its integration with immunotherapy approaches\, including CAR-T cell therapy. Through state-of-the-art updates and clinical perspectives\, the course aims to equip clinicians with practical insights for optimizing diagnostic accuracy and therapeutic outcomes in this complex pediatric malignancy. \n\n\n\n \n\n\n\n \n\n\n\n \n\n\n\n\n\n\n\nRegister nowEnrol in the live webinar now for free! Register now\n\n\n\n\n\n\n\n \n\n\n\n \n\n\n\nLearning Objectives\n\n\n\n \n\n\n\n \n\n\n\n \n\n\n\n\nDescribe recent instrumental and radiopharmaceutical innovations in the diagnosis and management of neuroblastoma.\n\n\n\nCompare the clinical indications\, advantages\, and limitations of MIBG\, MFBF\, FDOPA\, and Gallium-based imaging tracers in neuroblastoma.\n\n\n\nEvaluate how emerging imaging techniques are changing staging\, risk stratification\, and treatment response assessment in pediatric patients.\n\n\n\nIdentify current challenges and unmet needs faced by pediatric oncologists and nuclear medicine physicians in integrating new diagnostic tools into clinical practice.\n\n\n\nDiscuss the principles and clinical applications of radioligand therapy in refractory and relapsed neuroblastoma.\n\n\n\nAssess the potential role of combined treatment strategies\, including radioligand therapy with immunotherapy and CAR-T cell therapy\, in improving patient outcomes.\n\n\n\nApply multidisciplinary decision-making approaches to optimize personalized diagnostic and therapeutic strategies for children with neuroblastoma.\n\n\n\n\n \n\n\n\n \n\n\n\nTarget Audience\n\n\n\n \n\n\n\n \n\n\n\n \n\n\n\n\nNuclear Medicine Physicians\n\n\n\n\n \n\n\n\n \n\n\n\nSuggested Reading\n\n\n\n \n\n\n\nSe Whee Sammy Park et al. Front Oncol 14:1408729. doi: 10.3389/fonc.2024.1408729 \, Lise Borgwardt et al\, The Journal of Nuclear Medicine (2024). DOI: 10.2967/jnumed.123.267256   \n\n\n\n \n\n\n\n\n\n\n\n \n\n\n\nFaculty\n\n\n\n \n\n\n\n \n\n\n\n\n\nJulian RogaschSpeaker \n\n\n\n\n\nBart de KeizerSpeaker \n\n\n\n\n\nMarie LuporsiModerator \n\n\n\n\n\n\n\n\n\nEvent Overview
URL:https://esmit.eanm.org/event/innovations-in-theranostics-for-neuroblastoma/
CATEGORIES:Live Webinars
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Vienna:20251212T133000
DTEND;TZID=Europe/Vienna:20251212T143000
DTSTAMP:20260419T052443
CREATED:20241017T081824Z
LAST-MODIFIED:20251204T110136Z
UID:1944-1765546200-1765549800@esmit.eanm.org
SUMMARY:To AI or not to AI in Neurology: That is the Question
DESCRIPTION:This webinar will explore state-of-the-art AI approaches for advancing neuroimaging\, with a particular focus on quantitative PET. It will cover the entire imaging pipeline\, from preprocessing\, acquisition\, and tomographic reconstruction to quantification\, segmentation\, denoising\, and resolution enhancement\, demonstrating how modern AI can enable more reproducible and robust brain PET biomarkers. Through two expert presentations and practical case examples\, the webinar will showcase how AI-driven methodologies are reshaping neuroimaging research and supporting more accurate diagnosis and disease monitoring. \n\n\n\n \n\n\n\n \n\n\n\n\n\n\n\nRegister nowEnrol in the live webinar now for free! Register now\n\n\n\n\n\n\n\n \n\n\n\n \n\n\n\nLearning Objectives\n\n\n\n \n\n\n\n\nLearn the principles behind AI-based quantitative PET methods\n\n\n\nUnderstand how AI can enhance each stage of the neuroimaging pipeline\, from preprocessing and reconstruction to segmentation\, denoising\, and resolution recovery.\n\n\n\nCritically assess when AI meaningfully improves neuroimaging workflows\n\n\n\nRecognize emerging opportunities and challenges in integrating AI tools into brain PET\n\n\n\n\n \n\n\n\n \n\n\n\nTarget Audience\n\n\n\n \n\n\n\nNuclear physicians\, medical physicists\, imaging scientists and radiologists working in PET neuroimaging \n\n\n\n \n\n\n\nFaculty\n\n\n\n \n\n\n\n\n\nPablo Aguilar FernándezModerator \n\n\n\n\n\nDimitris VisvikisSpeaker \n\n\n\n\n\nCharalampos TsoumpasSpeaker \n\n\n\n\n\n\n\n\n\nEvent Overview
URL:https://esmit.eanm.org/event/to-ai-or-not-to-ai-in-neurology-that-is-the-question/
CATEGORIES:AI & Quantification,Live Webinars
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Vienna:20251201T100000
DTEND;TZID=Europe/Vienna:20251201T110000
DTSTAMP:20260419T052443
CREATED:20250513T093530Z
LAST-MODIFIED:20251118T083337Z
UID:2534-1764583200-1764586800@esmit.eanm.org
SUMMARY:Japanese vs. European View on Targeted Radionuclide Therapy
DESCRIPTION:This event is a collaboration between ESMIT and JSNM. The aim of the webinar is to compare the approach to targeted radionuclide therapy (TRT) in Japan and in Europe. The webinar will focus on the differences in the TRT environment in Japan vs. Europe\, including regulatory science and radiation protection regulation\, and more. \n\n\n\n \n\n\n\n \n\n\n\n\n\n\n\nRegister nowEnrol in the live webinar now for free! Register now\n\n\n\n\n\n\n\n \n\n\n\n \n\n\n\nTarget Audience\n\n\n\n \n\n\n\nNuclear Medicine Physicians \n\n\n\n \n\n\n\nFaculty\n\n\n\n\nTatsuya HigashiSpeaker \n\n\n\nWolfgang FendlerSpeaker \n\n\n\nConrad-Amadeus VoltinModerator \n\n\n\n\n\n\n\n\nEvent Overview
URL:https://esmit.eanm.org/event/japanese-vs-european-view-on-targeted-radionuclide-therapy/
CATEGORIES:Clinical Nuclear Medicine,Live Webinars
ORGANIZER;CN="ESMIT":MAILTO:esmit@eanm.org
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Vienna:20251114T133000
DTEND;TZID=Europe/Vienna:20251114T143000
DTSTAMP:20260419T052443
CREATED:20241017T081732Z
LAST-MODIFIED:20251112T090155Z
UID:1942-1763127000-1763130600@esmit.eanm.org
SUMMARY:Paediatric Thyroid Cancer
DESCRIPTION:This webinar aims to underly the most relevant differences with the adults DCT regarding epidemiology\, genetics\, pathology\, immunoistopathology\, diagnostic tools and treatment\, especially for RAI theranostic procedure. Additionally\, the webinar will also go over the main GL recommendations\, as well as present and discuss two emblematic or tricky cases. \n\n\n\n \n\n\n\n \n\n\n\n\n\n\n\nRegister nowEnrol in the live webinar now for free! Register now\n\n\n\n\n\n\n\n \n\n\n\n \n\n\n\n \n\n\n\nLearning Objectives\n\n\n\n \n\n\n\n \n\n\n\n\nThe aim of this course is to sensitise the attendees about the correct way to recognise\, diagnose and treat DTC in children.\n\n\n\n\n \n\n\n\n \n\n\n\nTarget Audience\n\n\n\n \n\n\n\n \n\n\n\n\nPhysicians\, residents with special interest on endocrinlogy and endo-oncology\, nuclear medicine specialists\, nurses and technicians of nuclear medicine units.\n\n\n\n\n \n\n\n\n \n\n\n\n \n\n\n\nSuggested Readings\n\n\n\n \n\n\n\n \n\n\n\n\nFrancis GL\, Waguespack SG\, Bauer AJ\, Angelos P\, Benvenga S\, Cerutti JM\, Dinauer CA\, Hamilton J\, Hay ID\, Luster M\, Parisi MT\, Rachmiel M\, Thompson GB\, Yamashita S; American Thyroid Association Guidelines Task Force. Management Guidelines for Children with Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid. 2015 Jul;25(7):716-59. doi: 10.1089/thy.2014.0460. PMID: 25900731; PMCID: PMC4854274.\n\n\n\nLebbink CA\, Links TP\, Czarniecka A\, Dias RP\, Elisei R\, Izatt L\, Krude H\, Lorenz K\, Luster M\, Newbold K\, Piccardo A\, Sobrinho-Simões M\, Takano T\, Paul van Trotsenburg AS\, Verburg FA\, van Santen HM. 2022 European Thyroid Association Guidelines for the management of pediatric thyroid nodules and differentiated thyroid carcinoma. Eur Thyroid J. 2022 Nov 29;11(6):e220146. doi: 10.1530/ETJ-22-0146. PMID: 36228315; PMCID: PMC9716393.\n\n\n\nCzarniecka A\, Woźniak G\, Kropińska A\, Jarząb B\, Handkiewicz-Junak D. Surgical approach to differentiated thyroid cancers (DTC) in children [Specyfika leczenia chirurgicznego zróżnicowanych raków tarczycy (ZRT) u dzieci]. Endokrynol Pol. 2019;70(4):357-366. doi: 10.5603/EP.a2019.0033. PMID: 31489960.\n\n\n\n\n \n\n\n\n \n\n\n\n \n\n\n\nFaculty\n\n\n\n\n\nDesiree DeandreisSpeaker \n\n\n\n\n\nCatia OliantiModerator \n\n\n\n\n\nLivia LamartinaSpeaker \n\n\n\n\n\n\n\n\n\n \n\n\n\n \n\n\n\nEvent Overview
URL:https://esmit.eanm.org/event/paediatric-thyroid-cancer/
CATEGORIES:Clinical Nuclear Medicine,Live Webinars
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Vienna:20251107T133000
DTEND;TZID=Europe/Vienna:20251107T143000
DTSTAMP:20260419T052443
CREATED:20241017T081503Z
LAST-MODIFIED:20251104T110112Z
UID:1940-1762522200-1762525800@esmit.eanm.org
SUMMARY:Nuclear Medicine-related Highlights from ESMO 2025
DESCRIPTION:This ESMO 2025 webinar will cover a range of topics\, including the latest advancements treatment options\, imaging modalities and performant tracers related to solid and liquid tumors. The focus of this Live event will be the recent advances in solid & liquid tumor treatment\, clinical trials and emerging therapies\, biomarkers in solid tumors and multidisciplinary approaches. The importance of collaboration among medical oncologists\, radiologists\, nuclear medicine physicians\, pathologists and surgeons will be underlined\, based on clinical examples. Challenges and opportunities in immunotherapy for solid tumors will also be addressed\, with special attention for personalized treatment plans in specific cancers\, like lung cancer\, breast cancer\, colorectal and prostate cancer. \n\n\n\nPlease note that the webinar will be recorded\, and the recording will be available a few days after the session is over. You can find the recording on the ESMIT E-learning platform\, under the webinar title. A handout of the presentation materials will also be available on the platform. \n\n\n\n \n\n\n\n \n\n\n\n \n\n\n\n \n\n\n\n\n\n\n\nRegister nowEnrol in the live webinar now for free! Register now\n\n\n\n\n\n\n\n \n\n\n\n \n\n\n\n \n\n\n\nLearning Objectives\n\n\n\n \n\n\n\n\nAttendees will get insight into recent advances in solid/ liquid tumor treatment\n\n\n\nAttendees will be familiarized with the latest developments when diagnosing\, staging and treating different types of solid and liquid tumors.\n\n\n\n\n \n\n\n\n \n\n\n\nTarget Audience\n\n\n\n \n\n\n\n\nFellows and Medical Specialists in Nuclear Medicine\, Radiology\, Medical Oncology\, Urology\, Surgery\, Pathology and Radiation Oncology\n\n\n\n\n \n\n\n\n \n\n\n\n \n\n\n\nFaculty\n\n\n\n \n\n\n\n\n\nDavid KerstingModerator \n\n\n\n\n\nKarolien GoffinSpeaker \n\n\n\n\n\nMatthias EiberSpeaker \n\n\n\n\n\n\n\n\n\n \n\n\n\nEvent Overview
URL:https://esmit.eanm.org/event/nuclear-medicine-related-highlights-from-esmo-2025/
CATEGORIES:Clinical Nuclear Medicine,Live Webinars
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Vienna:20251024T133000
DTEND;TZID=Europe/Vienna:20251024T143000
DTSTAMP:20260419T052443
CREATED:20241017T081404Z
LAST-MODIFIED:20251020T094434Z
UID:1938-1761312600-1761316200@esmit.eanm.org
SUMMARY:Explainable AI
DESCRIPTION:The webinar will provide first the fundamentals and basics of explainable artificial intelligence\, including the tools for interpretability of machine and deep learning models\, as well as the explainability principles. Second\, it will provide how these concepts are translated and applied to the development of AI-based models for nuclear medicine applications. \n\n\n\n \n\n\n\n\n\n\n\nRegister nowEnrol in the live webinar now for free! Register now\n\n\n\n\n\n\n\n \n\n\n\n \n\n\n\nLearning Objectives\n\n\n\n \n\n\n\n \n\n\n\n\nAttendees will be able to understand what are the concepts and methods that define explainable AI\, including interpretability tools and algorithms\, as well as explainability concepts to translate these to the end-users.\n\n\n\nAttendees will be able to discover how these concepts can be used to facilitate the development\, adoption and trust for end-users of AI-based models in nuclear medicine applications.\n\n\n\n\n \n\n\n\n \n\n\n\n \n\n\n\n \n\n\n\nTarget Audience\n\n\n\n \n\n\n\n \n\n\n\n\nNuclear medicine physicians\, scientists and technologists interested in the application of artificial intelligence in nuclear medicine imaging applications.\n\n\n\n\n \n\n\n\n \n\n\n\nFaculty\n\n\n\n\n\nNeo Christopher ChungSpeaker \n\n\n\n\n\nClemens SpielvogelSpeaker \n\n\n\n\n\nMathieu HattModerator \n\n\n\n\n\n\n\n\n\nEvent Overview
URL:https://esmit.eanm.org/event/explainable-ai/
CATEGORIES:AI & Quantification,Live Webinars
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Vienna:20250919T133000
DTEND;TZID=Europe/Vienna:20250919T143000
DTSTAMP:20260419T052443
CREATED:20250225T110337Z
LAST-MODIFIED:20250911T085022Z
UID:2253-1758288600-1758292200@esmit.eanm.org
SUMMARY:Radiation Safety for Oncological Patients before and after Nuclear Medicine Procedures and Radiation Safety of Nursing Staff
DESCRIPTION:This webinar will emphasize the critical importance of radiation protection in safeguarding both the occupational health of care providers and the well-being of patients undergoing radionuclide therapy. \n\n\n\nIt will underscore the necessity of adhering to established guidelines and protocols when handling radioactive materials to ensure safety and treatment efficacy. \n\n\n\nFurthermore\, the session will explore the role of interprofessional collaboration and continuing education among health care providers in enhancing radiation safety practices. It will also present evidence-based strategies to mitigate patients’ symptoms associated with the adverse effects of radionuclide treatment. \n\n\n\n\n\n\n\n \n\n\n\nRegister now!Enrol in the live webinar now for free! Register now\n\n\n\n \n\n\n\n \n\n\n\n\n\n\n\n \n\n\n\nLearning Objectives\n\n\n\n \n\n\n\n\nTo identify the primary steps for introducing newly hired health care staff to radionuclide therapy protocols and recognize the importance of continuous education in maintaining adherence to institutional safety and procedural standards.\n\n\n\nTo evaluate various educational methods and strategies used to train health care providers—including nurses\, caregivers\, seasonal workers\, and clinical assistants—in the principles\, procedures\, and safety protocols of radionuclide therapy.\n\n\n\nTo demonstrate effective patient education techniques and symptom management strategies for individuals undergoing radionuclide therapy\, with attention to minimizing adverse effects and enhancing patient comprehension.\n\n\n\nTo compare different radiation safety protocols and clinical guidelines associated with Lutathera and radioiodine therapies\, with respect to implications for both patients and health care providers.\n\n\n\n\n \n\n\n\n \n\n\n\nTarget Audience\n\n\n\n \n\n\n\n \n\n\n\nAll health care providers involved in the care of oncological patients undergoing radionuclide treatment in clinical practice \n\n\n\n \n\n\n\n\n\n\n\n \n\n\n\nFaculty\n\n\n\n \n\n\n\n \n\n\n\n\n\nLace MatarloSpeaker \n\n\n\n\n\nMatthias Hellberg-NaegeleModerator \n\n\n\n\n\nSigrid Leide SvegbornSpeaker
URL:https://esmit.eanm.org/event/radiation-safety-for-oncological-patients-before-and-after-nuclear-medicine-procedures-and-radiation-safety-of-nursing-staff/
CATEGORIES:Clinical Nuclear Medicine,Live Webinars
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Vienna:20250829T133000
DTEND;TZID=Europe/Vienna:20250829T143000
DTSTAMP:20260419T052443
CREATED:20250225T102510Z
LAST-MODIFIED:20250812T114908Z
UID:2248-1756474200-1756477800@esmit.eanm.org
SUMMARY:Technical Aspects of Parenteral Administration of Radiopharmaceuticals to Oncological Patients
DESCRIPTION:For performing the PET/CT examination\, the administration of radiopharmaceutical as unavoidable for imaging with PET. Inversely\, the administration of contrast agent to improve the quality of CT part of PET/CT as optional.  The accurate intravenous administration of diagnostic radiopharmaceutical (and optionally of contrast agent) may be challenging in some cases\, in particular in patients with compromised peripheral venous access after several lines of treatments. In order to increase the patient comfort and to simplify the intravenous administration of medicines\, several types of long-term venous access have been developed. \n\n\n\n\n\n\n\nRegister nowEnrol in the live webinar now for free! Register now!\n\n\n\n\n\n\n\n \n\n\n\n \n\n\n\n \n\n\n\nLearning Objectives\n\n\n\n \n\n\n\n\nTo understand the different types of currently available long-term venous accesses\n\n\n\nTo understand the principles of safe and correct handling of long-term venous access in patient referred for PET/CT\n\n\n\n\n \n\n\n\n \n\n\n\nTarget Audience\n\n\n\n \n\n\n\nNuclear Medicine Professionals \n\n\n\n \n\n\n\n \n\n\n\nFaculty\n\n\n\n \n\n\n\n\n\nEugenia TrigosoSpeaker \n\n\n\n\n\nSona BalogovaSpeaker \n\n\n\n\n\nConrad-Amadeus VoltinModerator \n\n\n\n\n\n\n\n\n\nEvent Overview
URL:https://esmit.eanm.org/event/technical-aspects-of-parenteral-administration-of-radiopharmaceuticals-to-oncological-patients/
CATEGORIES:Instrumentation, Technology, Science,Live Webinars
ORGANIZER;CN="ESMIT":MAILTO:esmit@eanm.org
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Vienna:20250704T133000
DTEND;TZID=Europe/Vienna:20250704T143000
DTSTAMP:20260419T052443
CREATED:20241017T075136Z
LAST-MODIFIED:20250630T084441Z
UID:1917-1751635800-1751639400@esmit.eanm.org
SUMMARY:Alpha Emitters – The Roadmap of the Big Ones!
DESCRIPTION:The purpose of this seminar is to provide a comprehensive overview of radionuclide therapy using alpha-emitting isotopes\, focusing on their current clinical and preclinical applications. It will explore the unique advantages of alpha emitters\, such as their high linear energy transfer and short path length\, which allow for precise tumor cell killing with minimal damage to surrounding tissue. The seminar will also address key challenges\, including limited availability of suitable alpha-emitting radionuclides\, complex radiochemistry\, and safety concerns during production and handling. Emphasis will be placed on production routes\, chelation strategies\, and conjugation chemistry that enable targeted delivery to cancer cells. Finally\, the session will critically evaluate the therapeutic potential and limitations of alpha therapy\, highlighting areas for future research and clinical translation. \n\n\n\n \n\n\n\n \n\n\n\n\n\n\n\nRegister nowEnrol in the live webinar now for free! Register now\n\n\n\n\n\n\n\n \n\n\n\n \n\n\n\nLearning Objectives\n\n\n\n \n\n\n\n\nParticipants will gain understanding of the advantages of alpha-emitters over beta emitter\n\n\n\nParticipants will be able to describe and explain challenges arising from applications of alpha-emitters\n\n\n\n\n \n\n\n\n \n\n\n\nTarget Audience\n\n\n\n \n\n\n\n\nRadiochemist\, Radiopharmacists\, nuclear physicians with a research profile\, medicinal chemistry researchers\n\n\n\n\n \n\n\n\n \n\n\n\nFaculty\n\n\n\n \n\n\n\n\n\nMatthias HerthSpeaker \n\n\n\n\n\nFilipe ElvasSpeaker \n\n\n\n\n\nDana NiculaeModerator \n\n\n\n\n\n\n\n\n\nEvent Overview
URL:https://esmit.eanm.org/event/alpha-emitters-the-roadmap-of-the-big-ones/
CATEGORIES:Live Webinars,Radiopharmaceuticals
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Vienna:20250627T133000
DTEND;TZID=Europe/Vienna:20250627T143000
DTSTAMP:20260419T052443
CREATED:20241017T080743Z
LAST-MODIFIED:20250624T092530Z
UID:1932-1751031000-1751034600@esmit.eanm.org
SUMMARY:Extravascular Administration in Diagnostic and Therapeutic Nuclear Medicine
DESCRIPTION:In nuclear medicine\, diagnostic as well as therapeutic\, radiopharmaceuticals are administered via an intravenous injection\, in a majority of the procedures in a blood vessel at the crook of the arm or on the back of the hand. Occasionally\, the injection fails\, which results in the radiopharmaceutical ending up extravascularly. The consequence of this may be a locally high radiation dose at the injection site\, in some situations high enough to cause severe tissue effects on the patient. Thus\, it is important to recognize the problem and identify the cause in order to decrease the risk. Furthermore\, the management of the situation after such an extravasation must be dealt with thoroughly and this has been the subject of lively debate in recent years. The parameters that have an impact on the radiation dose are among other things\, the physical properties of the radionuclide\, as well as the activity and volume of the radioactive substance retained in the surroundings of the blood vessel. In the case when most of the administered activity ends up extravascular\, the quality of the diagnostic procedure or the effect of the treatment are negatively affected\, which must be addressed. \n\n\n\n \n\n\n\n \n\n\n\n\n\n\n\nRegister nowEnrol in the live webinar now for free! Register now\n\n\n\n\n\n\n\n \n\n\n\n \n\n\n\nLearning Objectives\n\n\n\n \n\n\n\n \n\n\n\nThe aim of this webinar is to highlight the risk and consequences of extravascular administration of radiopharmaceuticals as well as the management of the situation after an extravasation. \n\n\n\n \n\n\n\nTarget Audience\n\n\n\n \n\n\n\nPhysicists\, Physicians\, Technologists\, Nurses \n\n\n\n \n\n\n\n \n\n\n\nFaculty\n\n\n\n \n\n\n\n\n\nSiria MediciSpeaker \n\n\n\n\n\nJochem van der Pol Speaker \n\n\n\n\n\nSigrid Leide SvegbornModerator \n\n\n\n\n\n\n\n\n\nEvent Overview
URL:https://esmit.eanm.org/event/extravascular-administration-in-diagnostic-and-therapeutic-nuclear-medicine/
CATEGORIES:Instrumentation, Technology, Science,Live Webinars
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Vienna:20250613T133000
DTEND;TZID=Europe/Vienna:20250613T143000
DTSTAMP:20260419T052443
CREATED:20241017T081027Z
LAST-MODIFIED:20250605T095541Z
UID:1934-1749821400-1749825000@esmit.eanm.org
SUMMARY:Cardiac Amyloidosis Imaging: Do We Need Quantification?
DESCRIPTION:This webinar provides an overview of the diagnosis of cardiac amyloidosis in nuclear cardiology . Background information on amyloidosis in general is presented and typical disease manifestations are discussed. Furthermore\, the significance of cardiac amyloidosis will be discussed in detail and possible therapeutic options will be explained. In this context\, the relevance of quantification to characterize disease and how to assess reliably the effects of therapy are presented. \n\n\n\n \n\n\n\n\n\n\n\nRegister nowEnrol in the live webinar now for free! Register now\n\n\n\n\n\n\n\n \n\n\n\n \n\n\n\nLearning Objectives\n\n\n\n \n\n\n\n\nTo gain a insight into the disease of amyloidosis and in particular the cardiac involvement of amyloidosis.\n\n\n\nTo learn the possibilities of quantification of planar and SPECT studies in amyloidosis\n\n\n\n\n \n\n\n\n \n\n\n\nTarget Audience\n\n\n\n \n\n\n\n\nNuclear physicians\, cardiologists\, internists and radiologists who are interested in amyloidosis and want to deepen their knowledge of cardiac amyloidosis diagnostics and quantification\n\n\n\n\n \n\n\n\n \n\n\n\nFaculty\n\n\n\n \n\n\n\n\n\nFederico CaobelliSpeaker \n\n\n\n\n\nIan ArmstrongSpeaker \n\n\n\n\n\nCarmela NappiModerator \n\n\n\n\n\nStephan NekollaModerator \n\n\n\n\n\n\n\n\n\nEvent Overview
URL:https://esmit.eanm.org/event/cardiac-amyloidosis-imaging-do-we-need-quantification/
CATEGORIES:AI & Quantification,Live Webinars
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Vienna:20250509T133000
DTEND;TZID=Europe/Vienna:20250509T143000
DTSTAMP:20260419T052443
CREATED:20241017T080513Z
LAST-MODIFIED:20250505T100056Z
UID:1930-1746797400-1746801000@esmit.eanm.org
SUMMARY:Introducing Dosimetry in the Clinical Setting
DESCRIPTION:This course presents and discusses the requirements and methods to enable and perform personalized dosimetry in nuclear medicine therapy. \n\n\n\n \n\n\n\n\n\n\n\nRegister nowEnrol in the live webinar now for free! Register now\n\n\n\n \n\n\n\n\n\n\n\n \n\n\n\nLearning Objectives\n\n\n\n \n\n\n\nThe aim of this course is to provide tools and methods to implement personalized dosimetry in a clinical setup. \n\n\n\n \n\n\n\nTarget Audience\n\n\n\n \n\n\n\nNuclear medicine clinicians and medical physicists \n\n\n\n \n\n\n\nSuggested Readings\n\n\n\n \n\n\n\n“EANM enabling guide: how to improve the accessibility of clinical dosimetry.” Results from an EANM survey on time estimates and personnel responsible for main tasks in molecular radiotherapy dosimetry \n\n\n\n\nClick Here\n\n\n\n\n \n\n\n\n \n\n\n\nFaculty\n\n\n\n \n\n\n\n\n\nJonathan GearSpeaker \n\n\n\n\n\nPablo Mínguez GabiñaSpeaker \n\n\n\n\n\nEivor HernesSpeaker \n\n\n\n\n\nSilvano GnesinModerator \n\n\n\n\n\n\n\n\n\n \n\n\n\nEvent Overview
URL:https://esmit.eanm.org/event/introducing-dosimetry-in-the-clinical-setting/
CATEGORIES:AI & Quantification,Live Webinars
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Vienna:20250425T133000
DTEND;TZID=Europe/Vienna:20250425T143000
DTSTAMP:20260419T052443
CREATED:20241017T081307Z
LAST-MODIFIED:20250214T105155Z
UID:1936-1745587800-1745591400@esmit.eanm.org
SUMMARY:Highlights of Focus Meeting 6: Shaping the Future of Breast Cancer Care with Molecular Imaging (pre-recorded)
DESCRIPTION:more information coming soon \n\n\n\n\n\n\n\nRegister nowEnrol in the live webinar now for free! Register now\n\n\n\n\n\n\n\nFaculty\n\n\n\n\n\nSpeaker \n\n\n\n\n\nSpeaker \n\n\n\n\n\nSpeaker \n\n\n\n\n\n\n\n\n\nEvent Overview
URL:https://esmit.eanm.org/event/highlights-of-focus-meeting-6-shaping-the-future-of-breast-cancer-care-with-molecular-imaging-prerecorded/
CATEGORIES:Clinical Nuclear Medicine,Live Webinars
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Vienna:20250404T133000
DTEND;TZID=Europe/Vienna:20250404T143000
DTSTAMP:20260419T052443
CREATED:20241017T080415Z
LAST-MODIFIED:20250326T095143Z
UID:1928-1743773400-1743777000@esmit.eanm.org
SUMMARY:Radioiodine-Refractory Thyroid Cancer - Is it Time to Change the Definition in the Light of Novel Redifferentiation Therapies?
DESCRIPTION:This webinar explores the perspectives on radiorefractory thyroid cancer through two presentations. In the first talk the speaker challenges current diagnostic frameworks and proposes a new vision that better reflects the evolving understanding of refractory thyroid cancer. The second presentation offers a comprehensive review of emerging approaches to restore iodine avidity in radiorefractory thyroid cancer\, highlighting recent clinical trials\, molecular targeting techniques\, and potential promising combination therapies. \n\n\n\n \n\n\n\n \n\n\n\n \n\n\n\n\n\n\n\nRegister nowEnrol in the live webinar now for free! Register now\n\n\n\n\n\n\n\n \n\n\n\n \n\n\n\n \n\n\n\n \n\n\n\nLearning Objectives\n\n\n\n \n\n\n\n\nTo evaluate the current definition of radiorefractory thyroid cancer and identify its limitations in clinical practice\n\n\n\nTo learn new insights for radiorefractory thyroid cancer definition and their potential impact on treatment decisions\n\n\n\nTo learn current evidence-based redifferentiation strategies for restoring iodine avidity in radiorefractory thyroid cancer\n\n\n\nTo improve knowledge of redifferentiation mechanisms to develop personalized treatment plans for patients with radiorefractory thyroid cancer\n\n\n\n\n \n\n\n\n \n\n\n\n \n\n\n\nTarget Audience\n\n\n\n \n\n\n\n\nNuclear Medicine physicians\, Endocrinologist\, Oncologist \n\n\n\n\n \n\n\n\n \n\n\n\nFaculty\n\n\n\n \n\n\n\n \n\n\n\n\n\nPetra PetranovicSpeaker \n\n\n\n\n\nMichael KreisslSpeaker \n\n\n\n\n\nLuca GiovanellaModerator \n\n\n\n\n\n\n\n\n\n \n\n\n\n \n\n\n\nEvent Overview
URL:https://esmit.eanm.org/event/radioiodine-refractory-thyroid-cancer-is-it-time-to-change-the-definition-in-the-light-of-novel-redifferentiation-therapies/
CATEGORIES:Clinical Nuclear Medicine,Live Webinars
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Vienna:20250328T133000
DTEND;TZID=Europe/Vienna:20250328T143000
DTSTAMP:20260419T052443
CREATED:20241017T080209Z
LAST-MODIFIED:20250312T095042Z
UID:1926-1743168600-1743172200@esmit.eanm.org
SUMMARY:Theranostic Training: Practical and Methodological Concepts
DESCRIPTION:This webinar aims to introduce the concept of theranostics and provide an overview of its potential. Participants will gain an understanding of how our technological competencies contribute to and enhance theranostic processes\, and how we can leverage these strengths in practice. \n\n\n\nPlease note that the webinar will be recorded\, and the recording will be available a few days after the session is over. You can find the recording on the ESMIT E-learning platform\, under the webinar title. A handout of the presentation materials will also be available on the platform. \n\n\n\n \n\n\n\n \n\n\n\n \n\n\n\n \n\n\n\n\n\n\n\nRegister nowEnroll in the live webinar now for free! Register now\n\n\n\n\n\n\n\n \n\n\n\n \n\n\n\n \n\n\n\nLearning Objectives\n\n\n\n \n\n\n\n\nAttendees will understand the concept of theranostics and its significance in modern healthcare.\n\n\n\nAttendees will explore the foundational technologies behind theranostics and learn how departments can be organized to integrate theranostic procedures.\n\n\n\nAttendees will gain insights into the perspectives of physicians and technologists on theranostics and how these disciplines collaborate to deliver optimal patient outcomes.\n\n\n\n\n \n\n\n\n \n\n\n\nTarget Audience\n\n\n\n \n\n\n\n\nTechnologists\, Nurses\, Physicists\n\n\n\n\n \n\n\n\n \n\n\n\n \n\n\n\nFaculty\n\n\n\n \n\n\n\n\n\nRiccardo LaudicellaSpeaker \n\n\n\n\n\nDaniela FonsecaSpeaker \n\n\n\n\n\nAngelo CardosoModerator \n\n\n\n\n\nConrad-Amadeus VoltinModerator \n\n\n\n\n\n\n\n\n\n \n\n\n\nEvent Overview
URL:https://esmit.eanm.org/event/theranostic-training-for-technologists/
CATEGORIES:Live Webinars,Theranostics
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Vienna:20250307T133000
DTEND;TZID=Europe/Vienna:20250307T143000
DTSTAMP:20260419T052443
CREATED:20241017T080042Z
LAST-MODIFIED:20250224T082009Z
UID:1924-1741354200-1741357800@esmit.eanm.org
SUMMARY:Advantages of Long-Axial Field-of-View PET in Inflammation and Infection Imaging
DESCRIPTION:Long axial field of view (LAFOV) PET/CT is the latest development in PET instrumentation. This webinar will provide an overview of the clinical opportunities and applications of LAFOV PET in inflammation and infection imaging. \n\n\n\n\n\n\n\nRegister nowEnrol in the live webinar now for free! Register now\n\n\n\n\n\n\n\n \n\n\n\n \n\n\n\nLearning Objectives\n\n\n\n \n\n\n\n \n\n\n\n\nAttendees will be able to describe the main advantages of LAFOV PET in patients with inflammatory and infectious disorders.\n\n\n\nAttendees will be able to understand how the increased sensitivity of LAFOV PET/CT allows for faster scanning and/or an important reduction in injected activity\, and how it also enables dynamic whole-body PET imaging\, studying molecular interactions between organ systems and even delayed imaging.\n\n\n\nAttendees will be able to see that ultrafast imaging can facilitate imaging of new patient groups such as critically ill patients\, patients admitted to intensive care with persistent infection or children without sedation.\n\n\n\n\n \n\n\n\n \n\n\n\n \n\n\n\nTarget Audience\n\n\n\n \n\n\n\n \n\n\n\n\nNuclear Medicine Physicians\, Residents\, Technologists\n\n\n\n\n \n\n\n\nFaculty\n\n\n\n\n\nJoyce van SluisSpeaker \n\n\n\n\n\nLars GormsenSpeaker \n\n\n\n\n\nAndor GlaudemansSpeaker \n\n\n\n\n\nOliver GheysensModerator \n\n\n\n\n\n\n\n\n\nEvent Overview
URL:https://esmit.eanm.org/event/advantages-of-long-axial-field-of-view-pet-in-inflammation-and-infection-imaging/
CATEGORIES:Instrumentation, Technology, Science,Live Webinars
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Vienna:20250221T133000
DTEND;TZID=Europe/Vienna:20250221T143000
DTSTAMP:20260419T052443
CREATED:20241017T075932Z
LAST-MODIFIED:20250217T121048Z
UID:1922-1740144600-1740148200@esmit.eanm.org
SUMMARY:Surgery in Neuroendocrine Neoplasms (NENs)
DESCRIPTION:Neuroendocrine tumours (NETs) are a rare but clinically significant group of malignancies arising from neuroendocrine cells\, often presenting in the gastrointestinal tract or lungs. While NETs account for a small fraction of overall cancer cases\, their incidence is steadily rising. Radioguided surgery has emerged as a highly effective approach for treating NETs\, particularly in cases of primary tumours or oligometastatic disease\, where nuclear medicine imaging precisely localizes the lesions and surgical resection is feasible. \n\n\n\nThis session will explore the current landscape of radioguided surgery\, with a specific focus onneuroendocrine tumour applications. We will begin by reviewing the latest tracers and instrumentation employed in radioguided procedures\, discussing their mechanisms\, advantages\, and limitations. Following this\, we will delve into the clinical integration of these tracers and devices\, examining their role in the routine surgical workflow for NETs. By highlighting the practical implications and clinical outcomes\, this session aims to provide attendees with actionable insights into advancing care for patients with neuroendocrine tumours. \n\n\n\n \n\n\n\n\n\n\n\nRegister nowEnrol in the live webinar now for free! Register now\n\n\n\n\n\n\n\n\nLearning Objectives\n\n\n\n\n\nAttendees will be able to describe the latest advancements in radiotracers and surgical instrumentation for radioguided neuroendocrine tumour surgery\, including their mechanisms of action and clinical benefits. \n\n\n\nAttendees will be able to evaluate the indications for radioguided surgery in neuroendocrine tumours\, such as primary tumours and oligometastatic disease\, based on pre-operative nuclear medicine imaging. \n\n\n\nAttendees will be able to outline the steps required to integrate novel radiotracers and devices into the clinical workflow\, from surgical planning to intraoperative application\, with a focus on improving patient outcomes.\n\n\n\n\n\n\n\nTarget Audience\n\n\n\n\n\nSurgical oncologists\, nuclear medical physicians\, medical physicists\n\n\n\n\n\n\nFaculty\n\n\n\n\n\nThomas WendlerModerator \n\n\n\n\n\nPedro Fragoso Costa Speaker \n\n\n\n\n\nJohn Orozco CortesSpeaker \n\n\n\n\n\n\n\n\n\nEvent Overview
URL:https://esmit.eanm.org/event/surgery-in-neuroendocrine-neoplasms-nens/
CATEGORIES:Clinical Nuclear Medicine,Live Webinars
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Vienna:20250207T133000
DTEND;TZID=Europe/Vienna:20250207T143000
DTSTAMP:20260419T052443
CREATED:20241017T075631Z
LAST-MODIFIED:20250203T100308Z
UID:1920-1738935000-1738938600@esmit.eanm.org
SUMMARY:Bone Scan Beyond Oncological Disease
DESCRIPTION:The webinar primarily focuses on the clinical value and implementation of early phase SPECT-CT in non-oncological settings\, emphasizing its advantages over traditional planar imaging and late-phase bone scans. It highlights the diagnostic enhancement of early-phase imaging for inflammatory conditions\, pain assessment\, and soft-tissue evaluation. \n\n\n\nNew treatment options for cardiac amyloidosis are increasing interest in early diagnosis of the disease. DPD scan is an excellent and non-invasive diagnostic modality in this diagnosis\, but detailed local\, whole body and SPECT/CT including calculation of different ratios are necessary for an accurate diagnosis. The presentation showed the performance of the examination\, clinical and medical letter examples.  \n\n\n\n\n\n\n\nRegister nowEnrol in the live webinar now for free! Register now\n\n\n\n\n\n\n\nFaculty\n\n\n\n\n\nJules Zhang-YinSpeakerArlon\, Belgium \n\n\n\n\n\nKnut LiepeSpeakerFrankfurt (Oder)\, Germany \n\n\n\n\n\n\n\n\n\nEvent Overview
URL:https://esmit.eanm.org/event/bone-scan-beyond-oncological-disease/
CATEGORIES:Clinical Nuclear Medicine,Live Webinars
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Vienna:20241206T133000
DTEND;TZID=Europe/Vienna:20241206T143000
DTSTAMP:20260419T052443
CREATED:20240213T193126Z
LAST-MODIFIED:20241203T102334Z
UID:1300-1733491800-1733495400@esmit.eanm.org
SUMMARY:Treatment of Metastatic Bone Pain Using Bone-Seeking Agents
DESCRIPTION:With the arrival of new therapeutic tracers\, nuclear medicine has a new arsenal to treat metastatic bone pain. This presentation aims to give the keys to define the place of nuclear medicine among other treatment modalities (external beam therapy\, medical treatment\, chemotherapy). \n\n\n\nLearning Objectives: Refresh knowledge on the pathophysiology of pain and present the opportunities and limitations of alpha and beta therapy in metastatic bone pain treatment \n\n\n\n\n\n\n\nSave yourself a FREE seatEnter the eLearning store to register for the course. Having trouble? See the short tutorial here. Register now FOR FREE!\n\n\n\n\n\n\n\nFaculty\n\n\n\n\n\nJules Zhang-YinModeratorArlon\, Belgium \n\n\n\n\n\n\n\n\n\n\n\nKnut LiepeSpeakerFrankfurt (Oder)\, Germany \n\n\n\n\n\nTatiana LouroSpeakerLisbon\, Portugal \n\n\n\n\n\n\n\n\n\nRegistration\n\n\n\n\nmyEANM accountLog into your myEANM account or create a new one. \n\n\n\nESMIT eLearningAccess the eLearning platform. You can also navigate to it directly from your myEANM database: ESMIT→ESMIT Registrations \n\n\n\neLearning Course StoreEnter the course store\, make your selection and check out. \n\n\n\nEnroll yourselfFind your desired webinar under ‘Single Webinar Tickets’ or enroll for all 2024 webinars with the eLearning Access Plan – FREE OF CHARGE \n\n\n\nEnjoy!The link for the Zoom Webinar will be made available to you on the eLearning platform in the course contents \n\n\n\n\n\n\n\n\nEvent Overview
URL:https://esmit.eanm.org/event/treatment-of-metastatic-bone-pain-using-bone-seeking-agents-msk/
CATEGORIES:Clinical Nuclear Medicine,Live Webinars
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Vienna:20241202T100000
DTEND;TZID=Europe/Vienna:20241202T110000
DTSTAMP:20260419T052443
CREATED:20240702T080051Z
LAST-MODIFIED:20241119T122958Z
UID:1737-1733133600-1733137200@esmit.eanm.org
SUMMARY:Japanese vs. European View on Amyloid Imaging and Therapy (in collaboration with JSNM)
DESCRIPTION:The advent of FDA approved anti-AB drugs such as Aducanumab and Lecanemab is changing not only the therapeutic prospectives for patients but also the diagnostic flow-charts. However\, due to differences in clinical processes and insurance systems in each country\, the use of amyloid PET in the diagnostic tree currently varies from country to country. In Europe\, CSF diagnosis is often performed first and amyloid PET is performed in selected patients. In Japan\, only either CSF diagnosis or amyloid PET is covered by public insurance\, so there is a trend toward performing the more expensive PET first. The use of amyloid PET in the setting of anti-AB therapy monitoring\, and its exact positioning in the biomarkers  flow-chart is not yet clearly defined. This webinar will present recent findings on the usefulness of amyloid PET and the differences in actual use between Europe and Japan. \n\n\n\nLearning Objectives: tba \n\n\n\n\n\n\n\nSave yourself a FREE seatEnter the eLearning store to register for the course. Having trouble? See the short tutorial here. Register now FOR FREE!\n\n\n\n\n\n\n\nFaculty\n\n\n\n\n\nDonatienne Van WeehaegheModerator \n\n\n\n\n\n\n\n\n\n\n\nProf. Dr. med. Dr. biol. hum. Matthias Brendel\, MHBASpeakerDepartment leadBoard certified Nuclear Medicine physician Research lead for neurodegenerative disorders LMU Klinikum   Department of Nuclear MedicineUniversity Hospital of Munich \n\n\n\n\n\nDr. Kenji IshiiSpeakerDirectorDiagnostic Neuroimaging ResearchTokyo Metropolitan Institute for Geriatrics and GerontologyTokyo\, Japan \n\n\n\n\n\n\n\n\n\nRegistration\n\n\n\n\nmyEANM accountLog into your myEANM account or create a new one. \n\n\n\nESMIT eLearningAccess the eLearning platform. You can also navigate to it directly from your myEANM database: ESMIT→ESMIT Registrations \n\n\n\neLearning Course StoreEnter the course store\, make your selection and check out. \n\n\n\nEnroll yourselfFind your desired webinar under ‘Single Webinar Tickets’ or enroll for all 2024 webinars with the eLearning Access Plan – FREE OF CHARGE \n\n\n\nEnjoy!The link for the Zoom Webinar will be made available to you on the eLearning platform in the course contents \n\n\n\n\n\n\n\n\nEvent Overview
URL:https://esmit.eanm.org/event/japanese-vs-european-view-on-amyloid-imaging-and-therapy-in-collaboration-with-jsnm/
CATEGORIES:Clinical Nuclear Medicine,Live Webinars
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Vienna:20241122T133000
DTEND;TZID=Europe/Vienna:20241122T143000
DTSTAMP:20260419T052443
CREATED:20240213T192901Z
LAST-MODIFIED:20241004T123239Z
UID:1298-1732282200-1732285800@esmit.eanm.org
SUMMARY:Challenges of Zr89 Imaging
DESCRIPTION:While PET imaging with radionuclides such as F18 and Ga68 have proven to provide high quality diagnostic imaging\, imaging with other radionuclides can be more challenging. Zr-89 is one such radionuclide. Although Zr-89 has advantageous labelling properties for cell imaging and the imaging of monoclonal antibodies\, the radionuclide is non-ideal imaging qualities mostly due to its low dosage\, and also brings with it radiation safety challenges. This webinar will present both sides of Zr-89 imaging\, the clinically relevant opportunities for the radionuclide\, and the quantification challenges\, handling and the safety aspects of Zr-89. \n\n\n\nLearning Objectives: The aim of this webinar is to show the potential and the challenges of Zr-89 imaging. \n\n\n\n\n\n\n\nSave yourself a FREE seatEnter the eLearning store to register for the course. Having trouble? See the short tutorial here. Register now FOR FREE!\n\n\n\n\n\n\n\nFaculty\n\n\n\n\n\nFloris H.P. van VeldenModeratorLeiden\, Netherlands \n\n\n\n\n\nErik AarntzenSpeakerNijmegen\, Netherlands \n\n\n\n\n\nMarc C. HuismanSpeakerAmsterdam\, Netherlands \n\n\n\n\n\n\n\n\n\nRegistration\n\n\n\n\nmyEANM accountLog into your myEANM account or create a new one. \n\n\n\nESMIT eLearningAccess the eLearning platform. You can also navigate to it directly from your myEANM database: ESMIT→ESMIT Registrations \n\n\n\neLearning Course StoreEnter the course store\, make your selection and check out. \n\n\n\nEnroll yourselfFind your desired webinar under ‘Single Webinar Tickets’ or enroll for all 2024 webinars with the eLearning Access Plan – FREE OF CHARGE \n\n\n\nEnjoy!The link for the Zoom Webinar will be made available to you on the eLearning platform in the course contents \n\n\n\n\n\n\n\n\nEvent Overview
URL:https://esmit.eanm.org/event/challenges-of-zr89-imaging/
CATEGORIES:Live Webinars,Theranostics
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Vienna:20241108T133000
DTEND;TZID=Europe/Vienna:20241108T143000
DTSTAMP:20260419T052443
CREATED:20240213T192553Z
LAST-MODIFIED:20240723T085928Z
UID:1296-1731072600-1731076200@esmit.eanm.org
SUMMARY:Artificial Intelligence in Dosimetry
DESCRIPTION:The rapid development in machine learning has generated new artificial intelligence (AI) based methods for improving dosimetry within nuclear medicine. This webinar will present the current status of AI within the dosimetry workflow for targeted radionuclide therapy. First\, AI methods for reducing SPECT acquisition times\, noise reduction and scatter correction will be covered. Thereafter\, AI methods for organ segmentation and voxel-based dosimetry\, together with AI methods for pre-therapeutically dosimetry estimate will be highlighted. \n\n\n\nLearning Objectives: The aim of this webinar is to understand the basics of AI methodologies used for dosimetry and receive knowledge about the current status of AI applications within dosimetry for targeted radionuclide therapies. \n\n\n\n\n\n\n\nSave yourself a FREE seatEnter the eLearning store to register for the course. Having trouble? See the short tutorial here. Register now FOR FREE!\n\n\n\n\n\n\n\nFaculty\n\n\n\n\n\nPeter BernhardtModeratorGöteborg\, Sweden \n\n\n\n\n\n\n\n\n\n\n\nYuni Dewaraja  SpeakerMichigan\, USA \n\n\n\n\n\nJohannes Tran-GiaSpeakerWürzburg\, Germany \n\n\n\n\n\n\n\n\n\nRegistration\n\n\n\n\nmyEANM accountLog into your myEANM account or create a new one. \n\n\n\nESMIT eLearningAccess the eLearning platform. You can also navigate to it directly from your myEANM database: ESMIT→ESMIT Registrations \n\n\n\neLearning Course StoreEnter the course store\, make your selection and check out. \n\n\n\nEnroll yourselfFind your desired webinar under ‘Single Webinar Tickets’ or enroll for all 2024 webinars with the eLearning Access Plan – FREE OF CHARGE \n\n\n\nEnjoy!The link for the Zoom Webinar will be made available to you on the eLearning platform in the course contents \n\n\n\n\n\n\n\n\nEvent Overview
URL:https://esmit.eanm.org/event/artificial-intelligence-in-dosimetry/
CATEGORIES:AI & Quantification,Live Webinars
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Vienna:20240920T133000
DTEND;TZID=Europe/Vienna:20240920T143000
DTSTAMP:20260419T052443
CREATED:20240213T192107Z
LAST-MODIFIED:20240731T083213Z
UID:1294-1726839000-1726842600@esmit.eanm.org
SUMMARY:Paediatric Nuclear Medicine in Nephro-Urology
DESCRIPTION:The webinar will cover the most relevant methodological aspects of nuclear medicine techniques in paediatric nephrourology\, with particular attention to the choice of the radiotracer\, the correct patient preparation\, and the acquisition protocol. Some typical cases will show the main points of image processing and results visualization. The clinical part will deal with hydronephrosis and hydroureteronephrosis\, spacing from typical pelvicureteral junction obstruction to obstructive megaureter\, and some complex malformations\, such as duplex kidneys. The selected cases will pinpoint the critical clues used in interpreting and reporting the scintigraphic studies and the integration of scintigraphic data with other imaging modalities (ultrasounds\, MRI\, etc.) in evaluating paediatric nephrourology patients. \n\n\n\nLearning Objectives: The aim of this course is to review the methodology and the main indications for scintigraphic studies in paediatric nephro-urology\, taking into accounts the more relevant and recent international guidelines and offering various examples taken from the current clinical practice. \n\n\n\nSuggested Readings:1. The SNMMI and EANM Procedural Guidelines for Diuresis Renography in Infants and Children2. EANM procedural recommendations for managing the paediatric patient diagnostic nuclear medicine \n\n\n\n\n\n\n\nSave yourself a FREE seatEnter the eLearning store to register for the course. Having trouble? See the short tutorial here. Register now FOR FREE!\n\n\n\n\n\n\n\nFaculty\n\n\n\n\n\nDiego CecchinModeratorPadua\, Italy \n\n\n\n\n\nPietro ZucchettaSpeakerPadua\, Italy \n\n\n\n\n\n\n\n\n\nRegistration\n\n\n\n\nmyEANM accountLog into your myEANM account or create a new one. \n\n\n\nESMIT eLearningAccess the eLearning platform. You can also navigate to it directly from your myEANM database: ESMIT→ESMIT Registrations \n\n\n\neLearning Course StoreEnter the course store\, make your selection and check out. \n\n\n\nEnroll yourselfFind your desired webinar under ‘Single Webinar Tickets’ or enroll for all 2024 webinars with the eLearning Access Plan – FREE OF CHARGE \n\n\n\nEnjoy!The link for the Zoom Webinar will be made available to you on the eLearning platform in the course contents \n\n\n\n\n\n\n\n\nEvent Overview
URL:https://esmit.eanm.org/event/paediatric-nuclear-medicine-in-nephro-urology/
CATEGORIES:Clinical Nuclear Medicine,Live Webinars
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Vienna:20240906T133000
DTEND;TZID=Europe/Vienna:20240906T143000
DTSTAMP:20260419T052443
CREATED:20240213T191555Z
LAST-MODIFIED:20240710T090914Z
UID:1291-1725629400-1725633000@esmit.eanm.org
SUMMARY:FDG-PET/CT in Breast Cancer
DESCRIPTION:Breast cancer is the most common cancer in women worldwide and it is still one of the leading causes of morbi-mortality\, therefore being a major concern. 2-[18F]FDG PET/CT is commonly used in the clinical management of patients with breast cancer\, with significant impact on clinical management. Currently\, there is robust evidence supporting the usefulness of 2-[18F]FDG PET/CT in the initial staging of patients with locally advanced and metastatic breast cancer\, in the early assessment of treatment response and in the early detection of recurrence. The first presentation of this webinar will summarize the recently published “Joint EANM-SNMMI guideline on the role of 2-[18F]FDG PET/CT in no special type breast cancer” which was endorsed by other relevant societies in the subject of breast cancer (ACR\, ESSO\, ESTRO\, EUSOBI/ESR\, and EUSOMA). Updated information to support the recommendations to perform 2-[18F]FDG PET/CT in no special type breast cancer in different clinical settings will be provided. Despite no special type breast cancer presenting high 2-[18F]FDG avidity\, other breast cancer subtypes seem to be better evaluated with other PET radiopharmaceuticals. Therefore\, the second presentation will address the potential role of [18F]FES\, [89Zr]Trastuzumab\, [18F]Sodium fluoride (NaF)\, [18F]Fluciclovine (FACBC)\, [89Zr]Pembrolizumab and FAPI-ligands in breast cancer. During this webinar we want to brainstorm about the role of PET/CT in the different subtypes and clinical scenarios of patients with breast cancer. The webinar will be enriched by interactive clinical case discussion\, aiming to resemble the challenges found in daily clinical practice. \n\n\n\nLearning Objectives:  \n\n\n\n\nGeneral aspects to avoid false positive and false negative findings on 2-[18F]FDG PET/CT.\n\n\n\nDiagnostic accuracy of 2-[18F]FDG PET/CT compared to conventional imaging modalities.\n\n\n\nRecommendations for performing 2-[18F]FDG PET/CT in the initial staging\, in assessing response to therapy and in assessing recurrence.\n\n\n\nAppropriate PET radiopharmaceuticals to better address each breast cancer subtype.\n\n\n\nSpecific characteristics\, physiological biodistribution\, advantages and disadvantages of PET radiopharmaceuticals used in breast cancer beyond 2-[18F]FDG.\n\n\n\nGeneral interpretation criteria to optimize the information provided in the final PET/CT report.\n\n\n\n\n\n\n\n\nSave yourself a FREE seatEnter the eLearning store to register for the course. Having trouble? See the short tutorial here. Register now FOR FREE!\n\n\n\n\n\n\n\nFaculty\n\n\n\n\n\nLioe-Fee de Geus-OeiModeratorLeiden\, Netherlands \n\n\n\n\n\nSofia VazSpeakerLisbon\, Portugal \n\n\n\n\n\nLidija AntunovicSpeakerMilan\, Italy \n\n\n\n\n\n\n\n\n\nRegistration\n\n\n\n\nmyEANM accountLog into your myEANM account or create a new one. \n\n\n\nESMIT eLearningAccess the eLearning platform. You can also navigate to it directly from your myEANM database: ESMIT→ESMIT Registrations \n\n\n\neLearning Course StoreEnter the course store\, make your selection and check out. \n\n\n\nEnroll yourselfFind your desired webinar under ‘Single Webinar Tickets’ or enroll for all 2024 webinars with the eLearning Access Plan – FREE OF CHARGE \n\n\n\nEnjoy!The link for the Zoom Webinar will be made available to you on the eLearning platform in the course contents \n\n\n\n\n\n\n\n\nEvent Overview
URL:https://esmit.eanm.org/event/fdg-pet-ct-in-breast-cancer/
CATEGORIES:Clinical Nuclear Medicine,Live Webinars
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Vienna:20240705T133000
DTEND;TZID=Europe/Vienna:20240705T143000
DTSTAMP:20260419T052443
CREATED:20240213T191043Z
LAST-MODIFIED:20240701T122643Z
UID:1289-1720186200-1720189800@esmit.eanm.org
SUMMARY:Guidelines for the Use of FDG PET/CT in Infection and Inflammation 2.0
DESCRIPTION:General overview of the EANM/SNMMI guidelines on FDG PET/CT in inflammation and infection. \n\n\n\nLearning Objectives: The aim of this course is to summarize the major indications for FDG PET/CT in infection and inflammation\, based on the updated guidelines for nuclear medicine practice provided by the EANM/SNMMI. \n\n\n\n\n\n\n\nSave yourself a FREE seatEnter the eLearning store to register for the course. Having trouble? See the short tutorial here. Register now FOR FREE!\n\n\n\n\n\n\n\nFaculty\n\n\n\n\n\nAndor GlaudemansModeratorGroningen\, Netherlands \n\n\n\n\n\n\n\n\n\n\n\nOlivier GheysensSpeakerBrussels\, Belgium \n\n\n\n\n\nGad AbikhzerSpeakerMontreal\, Canada \n\n\n\n\n\n\n\n\n\nRegistration\n\n\n\n\nmyEANM accountLog into your myEANM account or create a new one. \n\n\n\nESMIT eLearningAccess the eLearning platform. You can also navigate to it directly from your myEANM database: ESMIT→ESMIT Registrations \n\n\n\neLearning Course StoreEnter the course store\, make your selection and check out. \n\n\n\nEnroll yourselfFind your desired webinar under ‘Single Webinar Tickets’ or enroll for all 2024 webinars with the eLearning Access Plan – FREE OF CHARGE \n\n\n\nEnjoy!The link for the Zoom Webinar will be made available to you on the eLearning platform in the course contents \n\n\n\n\n\n\n\n\nEvent Overview
URL:https://esmit.eanm.org/event/guidelines-for-the-use-of-fdg-pet-ct-in-infection-and-inflammation-2-0/
CATEGORIES:Clinical Nuclear Medicine,Live Webinars
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Vienna:20240614T133000
DTEND;TZID=Europe/Vienna:20240614T143000
DTSTAMP:20260419T052443
CREATED:20240213T190705Z
LAST-MODIFIED:20240611T073044Z
UID:1285-1718371800-1718375400@esmit.eanm.org
SUMMARY:Cardiovascular PET-CT and PET-MR Imaging
DESCRIPTION:Patients workflows and acquisition protocols in PET/CT and PET/MR with different radiotracers for cardiovascular nuclear medicine imaging. \n\n\n\nLearning Objectives: To learn how to manage radioactive generators 82Sr/82Rb and to acquire cardiovascular imaging in PET/CT or PET/MR and other acquisition protocols. \n\n\n\n\n\n\n\nSave yourself a FREE seatEnter the eLearning store to register for the course. Having trouble? See the short tutorial here. Register now FOR FREE!\n\n\n\n\n\n\n\nFaculty\n\n\n\n\n\nPaolo TurcoModeratorPadua\, Italy \n\n\n\n\n\nStephan NekollaModeratorMunich\, Germany \n\n\n\n\n\n\nSylvia SchachoffSpeakerMunich\, Germany \n\n\n\nIan ArmstrongSpeakerManchester\, UK \n\n\n\n\n\n\n\n\nRegistration\n\n\n\n\nmyEANM accountLog into your myEANM account or create a new one. \n\n\n\nESMIT eLearningAccess the eLearning platform. You can also navigate to it directly from your myEANM database: ESMIT→ESMIT Registrations \n\n\n\neLearning Course StoreEnter the course store\, make your selection and check out. \n\n\n\nEnroll yourselfFind your desired webinar under ‘Single Webinar Tickets’ or enroll for all 2024 webinars with the eLearning Access Plan – FREE OF CHARGE \n\n\n\nEnjoy!The link for the Zoom Webinar will be made available to you on the eLearning platform in the course contents \n\n\n\n\n\n\n\n\nEvent Overview
URL:https://esmit.eanm.org/event/cardiovascular-pet-ct-and-pet-mr-imaging/
CATEGORIES:Clinical Nuclear Medicine,Live Webinars
END:VEVENT
END:VCALENDAR